Meredith Jane Layton

Title: Meredith Jane Layton: Innovator in Leukaemia Research

Introduction

Meredith Jane Layton is a prominent inventor based in Tecoma, Australia. She has made significant contributions to the field of leukaemia research, holding two patents that showcase her innovative work. Her research focuses on the mechanisms of leukaemia inhibitory factors and their potential applications in medical science.

Latest Patents

Layton's latest patents include a method of use for murine leukaemia inhibitory factor-binding protein (mLBP). This invention relates to an isolated leukaemia inhibitory factor (LIF)-binding protein in soluble form, which is capable of inhibiting the ability of LIF from a second mammalian species to induce differentiation of M1 myeloid leukaemic cells in vitro. The second patent is centered around a receptor-binding determinant from leukaemia inhibitory factor. This invention involves molecules carrying binding determinants for the α-chain of the human leukaemia inhibitory factor binding receptor, which are designed to enhance the understanding of leukaemia treatment.

Career Highlights

Meredith Jane Layton has established herself as a key figure in her field through her innovative research and patent contributions. She is associated with Amrad Corporation Limited, where she continues to advance her work in leukaemia research.

Collaborations

Layton has collaborated with notable scientists, including Donald Metcalf and Nicos Anthony Nicola, further enhancing the impact of her research through teamwork and shared expertise.

Conclusion

Meredith Jane Layton's contributions to leukaemia research through her patents and collaborations highlight her role as an influential inventor in the scientific community. Her work continues to pave the way for advancements in medical treatments for leukaemia.